Dimensional Fund Advisors
CTKB icon

Dimensional Fund Advisors’s Cytek Biosciences CTKB Stock Holding History

Dimensional Fund Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6M Buy
2,663,329
+16,438
+0.6% +$77.6K ﹤0.01% 2200
2025
Q4 		$13.4M Sell
2,646,891
-570,897
-18% -$2.65M ﹤0.01% 2179
2025
Q3 		$11.2M Sell
3,217,788
-237,018
-7% -$890K ﹤0.01% 2264
2025
Q2 		$11.7M Buy
3,454,806
+600,997
+21% +$2M ﹤0.01% 2216
2025
Q1 		$11.4M Buy
2,853,809
+1,023,377
+56% +$5.3M ﹤0.01% 2193
2024
Q4 		$11.9M Buy
1,830,432
+262,607
+17% +$1.56M ﹤0.01% 2238
2024
Q3 		$8.68M Buy
1,567,825
+102,703
+7% +$582K ﹤0.01% 2357
2024
Q2 		$8.17M Buy
1,465,122
+89,615
+7% +$538K ﹤0.01% 2339
2024
Q1 		$9.23M Buy
1,375,507
+311,174
+29% +$2.46M ﹤0.01% 2340
2023
Q4 		$9.71M Buy
1,064,333
+153,592
+17% +$967K ﹤0.01% 2330
2023
Q3 		$5.03M Buy
910,741
+570,509
+168% +$4.58M ﹤0.01% 2529
2023
Q2 		$2.9M Buy
340,232
+176,695
+108% +$1.58M ﹤0.01% 2683
2023
Q1 		$1.5M Buy
+163,537
New +$1.76M ﹤0.01% 2810

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors's CTKB Position: Q1 2026 in Review

Dimensional Fund Advisors increased its Cytek Biosciences (CTKB) stake by 0.62% in Q1 2026, buying an estimated $77.6K and bringing the position to 2,663,329 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2200.

Dimensional Fund Advisors first reported a position in CTKB in Q1 2023 and has held it in 13 quarters since. The position peaked at $13.4M in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Dimensional Fund Advisors held 2,663,329 shares of Cytek Biosciences worth $11.6M as of Q1 2026.
  • Dimensional Fund Advisors bought 16,438 Cytek Biosciences shares in Q1 2026, an estimated $77.6K.
  • Cytek Biosciences made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2200 holding.
  • Dimensional Fund Advisors first reported a position in Cytek Biosciences in Q1 2023 and has held it in 13 quarters since.
  • Dimensional Fund Advisors's Cytek Biosciences position peaked at $13.4M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.